Spoken Alpha
Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals provides in-licensed diagnostic tests for celiac disease, respiratory infections, H. pylori, and hepatocellular carcinoma, with CE mark approval for European markets. The company previously developed rencofilstat, a cyclophilin inhibitor for chronic liver disease, but discontinued that program and sold related assets in 2025.
Hepion Pharmaceuticals, Inc is a Healthcare company operating in Biotechnology with a $1.6M market cap.
Most recent reported earnings: Q2 FY2025 (Aug 13, 2025).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add HEPA, reply to your welcome email and we'll prioritize it.
History
Spoken Alpha tracks HEPA's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 90% of the time
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for HEPA.
$ curl https://api.spokenalpha.com/v1/companies/HEPAFAQ
Spoken Alpha indexes HEPA's earnings call transcripts at https://spokenalpha.com/companies/HEPA. Each call links to attributed speakers and parsed analyst Q&A. Hepion Pharmaceuticals, Inc.'s own investor relations page is at https://hepionpharma.com/investors/.
Hepion Pharmaceuticals, Inc. (HEPA) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2025 | 2025-08-13 | $-0.09 | $0.00 | — | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-04-07 | $-11.11 | $-1.97 | -100.0% | $61.5K | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-11.12 | — | — | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-17 | $-0.72 | — | — | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-0.68 | — | — | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-04-15 | $-81.23 | $-131.50 | +38.2% | $109.7K | — | — | EODHD |
| Q4 FY2023 | 2024-01-05 | $-2.42 | $-2.63 | +8.0% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-19 | $-137.00 | $-156.00 | +12.2% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-184.00 | $-166.17 | -10.7% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-11 | $-174.00 | $-180.00 | +3.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-02-28 | $-1.80 | $-0.12 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-110.00 | $-170.00 | +35.3% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-260.00 | $-120.00 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-90.00 | $-130.00 | +30.8% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-01 | $-2.60 | $-0.13 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-120.00 | $-190.00 | +36.8% | $0 | — | — | EODHD |
| Q2 FY2021 | 2021-08-15 | $-0.10 | $-0.19 | +47.4% | $0 | — | — | EODHD |
| Q1 FY2021 | 2021-05-13 | $-120.00 | $-200.00 | +40.0% | $0 | — | — | EODHD |
| Q4 FY2020 | 2021-03-30 | $-0.29 | $-0.20 | -45.0% | $0 | — | — | EODHD |
| Q3 FY2020 | 2020-11-15 | $-690.00 | $-510.00 | -35.3% | $0 | — | — | EODHD |
Source: EODHD. HEPA reported actuals as published; sparse fields render as —.
When a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.68 | $1.21 | +38.7% | -1.2% | -1.2% |
| Q4 FY2026 | $1.90 | $1.38 | +37.5% | -2.3% | +0.2% |
| Q3 FY2026 | $1.87 | $1.38 | +35.8% | -3.3% | -5.9% |
| Q2 FY2026 | $1.70 | $1.35 | +25.6% | -1.4% | +1.5% |
| Q1 FY2025 | $1.73 | $1.34 | +29.3% | +1.5% | -1.2% |
OTHER since 2026 • 2/2 beats (100%) • last guidance cut Q2 FY2026
| Q4 FY2025 |
| $2.04 |
| $1.45 |
| +40.6% |
| -1.8% |
| +0.7% |
| Q3 FY2025 | $2.08 | $1.55 | +34.5% | -4.8% | -6.2% |
| Q2 FY2025 | $1.78 | $1.38 | +28.9% | -4.3% | -1.3% |
| Q1 FY2024 | $1.76 | $1.33 | +32.6% | -1.6% | +0.7% |
| Q4 FY2024 | $2.04 | $1.61 | +26.8% | -0.1% | +1.1% |